Literature DB >> 25342597

CYLD-mediated signaling and diseases.

Bryan J Mathis, Yimu Lai, Chen Qu, Joseph S Janicki, Taixing Cui1.   

Abstract

The conserved cylindromatosis (CYLD) codes for a deubiquitinating enzyme and is a crucial regulator of diverse cellular processes such as immune responses, inflammation, death, and proliferation. It directly regulates multiple key signaling cascades, such as the Nuclear Factor kappa B [NFkB] and the Mitogen-Activated Protein Kinase (MAPK) pathways, by its catalytic activity on polyubiquitinated key intermediates. Several lines of emerging evidence have linked CYLD to the pathogenesis of various maladies, including cancer, poor infection control, lung fibrosis, neural development, and now cardiovascular dysfunction. While CYLD-mediated signaling is cell type and stimuli specific, the activity of CYLD is tightly controlled by phosphorylation and other regulators such as Snail. This review explores a broad selection of current and past literature regarding CYLD's expression, function and regulation with emerging reports on its role in cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25342597      PMCID: PMC4418510          DOI: 10.2174/1389450115666141024152421

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  137 in total

Review 1.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

2.  GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma.

Authors:  S Kuphal; G Shaw-Hallgren; M Eberl; S Karrer; F Aberger; A K Bosserhoff; R Massoumi
Journal:  Oncogene       Date:  2011-05-16       Impact factor: 9.867

3.  Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation.

Authors:  William Reiley; Minying Zhang; Xuefeng Wu; Erica Granger; Shao-Cong Sun
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

4.  CYLD regulates spindle orientation by stabilizing astral microtubules and promoting dishevelled-NuMA-dynein/dynactin complex formation.

Authors:  Yunfan Yang; Min Liu; Dengwen Li; Jie Ran; Jinmin Gao; Shaojun Suo; Shao-Cong Sun; Jun Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

Review 5.  Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control.

Authors:  Ramin Massoumi; Ralf Paus
Journal:  Bioessays       Date:  2007-12       Impact factor: 4.345

6.  Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections.

Authors:  Jae Hyang Lim; Brigid Stirling; Jonathan Derry; Tomoaki Koga; Hirofumi Jono; Chang-Hoon Woo; Haodong Xu; Patricia Bourne; Un-Hwan Ha; Hajime Ishinaga; Haidong Xu; Ali Andalibi; Xin-Hua Feng; Hongguang Zhu; Yuxian Huang; Wenhong Zhang; Xinhua Weng; Chen Yan; Zhinan Yin; David E Briles; Roger J Davis; Richard A Flavell; Jian-Dong Li
Journal:  Immunity       Date:  2007-08       Impact factor: 31.745

7.  Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation.

Authors:  Young Sik Cho; Sreerupa Challa; David Moquin; Ryan Genga; Tathagat Dutta Ray; Melissa Guildford; Francis Ka-Ming Chan
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582

8.  CaMKII mediates recruitment and activation of the deubiquitinase CYLD at the postsynaptic density.

Authors:  Soe Thein; Jung-Hwa Tao-Cheng; Yan Li; K Ulrich Bayer; Thomas S Reese; Ayse Dosemeci
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

9.  PKCθ/β and CYLD are antagonistic partners in the NFκB and NFAT transactivation pathways in primary mouse CD3+ T lymphocytes.

Authors:  Nikolaus Thuille; Katarzyna Wachowicz; Natascha Hermann-Kleiter; Sandra Kaminski; Friedrich Fresser; Christina Lutz-Nicoladoni; Michael Leitges; Margot Thome; Ramin Massoumi; Gottfried Baier
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

10.  THE EXPERIMENTAL VASCULAR LESIONS PRODUCED BY BACILLUS MALLEI.

Authors:  C W Duval
Journal:  J Exp Med       Date:  1907-05-25       Impact factor: 14.307

View more
  36 in total

Review 1.  The role of deubiquitinating enzymes in spermatogenesis.

Authors:  Bharathi Suresh; Junwon Lee; Seok-Ho Hong; Kye-Seong Kim; Suresh Ramakrishna
Journal:  Cell Mol Life Sci       Date:  2015-09-08       Impact factor: 9.261

2.  CYLD exaggerates pressure overload-induced cardiomyopathy via suppressing autolysosome efflux in cardiomyocytes.

Authors:  Lei Qi; Huimei Zang; Weiwei Wu; Prakash Nagarkatti; Mitzi Nagarkatti; Qinghang Liu; Jeffrey Robbins; Xuejun Wang; Taixing Cui
Journal:  J Mol Cell Cardiol       Date:  2020-06-14       Impact factor: 5.000

Review 3.  30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology.

Authors:  Qian Zhang; Michael J Lenardo; David Baltimore
Journal:  Cell       Date:  2017-01-12       Impact factor: 41.582

4.  The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.

Authors:  Yan-Xiao Ji; Zan Huang; Xia Yang; Xiaozhan Wang; Ling-Ping Zhao; Pi-Xiao Wang; Xiao-Jing Zhang; Michele Alves-Bezerra; Lin Cai; Peng Zhang; Yue-Xin Lu; Lan Bai; Mao-Mao Gao; Huan Zhao; Song Tian; Yong Wang; Zhi-Xiang Huang; Xue-Yong Zhu; Yan Zhang; Jun Gong; Zhi-Gang She; Feng Li; David E Cohen; Hongliang Li
Journal:  Nat Med       Date:  2018-01-01       Impact factor: 53.440

Review 5.  CYLD, A20 and OTULIN deubiquitinases in NF-κB signaling and cell death: so similar, yet so different.

Authors:  Marie Lork; Kelly Verhelst; Rudi Beyaert
Journal:  Cell Death Differ       Date:  2017-03-31       Impact factor: 15.828

6.  Genetic alterations in TRAF3 and CYLD that regulate nuclear factor κB and interferon signaling define head and neck cancer subsets harboring human papillomavirus.

Authors:  Tony Chen; Jialing Zhang; Zhong Chen; Carter Van Waes
Journal:  Cancer       Date:  2017-03-13       Impact factor: 6.860

Review 7.  Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.

Authors:  Pavlína Janovská; Vítězslav Bryja
Journal:  Br J Pharmacol       Date:  2017-08-30       Impact factor: 8.739

8.  Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.

Authors:  M Hahn; J-P Bürckert; C A Luttenberger; S Klebow; M Hess; M Al-Maarri; M Vogt; S Reißig; M Hallek; A Wienecke-Baldacchino; T Buch; C P Muller; C P Pallasch; F T Wunderlich; A Waisman; N Hövelmeyer
Journal:  Leukemia       Date:  2017-06-01       Impact factor: 11.528

Review 9.  MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance.

Authors:  Ulrich H Weidle; Daniela Schmid; Fabian Birzele; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2020 Jan-Feb       Impact factor: 4.069

10.  UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling.

Authors:  Anushka Dikshit; Yingai J Jin; Simone Degan; Jihwan Hwang; Matthew W Foster; Chuan-Yuan Li; Jennifer Y Zhang
Journal:  Cancer Res       Date:  2018-09-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.